BACKGROUND: The pathogenesis of vasospasm (VS) post aneurysmal subarachnoid hemorrhage (SAH) is multifactorial and not completely understood. The authors hypothesize that circulating antiangiogenic factors play an important role in brain injury post SAH and that elevated levels predict the occurrence of symptomatic vasospasm. METHODS: In this study the authors measured the serum and cerebrospinal fluid (CSF) levels of soluble endoglin (sEng) and soluble fms-like tyrosine kinase 1 (sFlt1) in controls and SAH patients within 48 h of the bleed. Patients were prospectively followed and subcategorized into those with (sVS) and without symptomatic vasospasm (no-sVS). RESULTS: Compared to healthy controls, SAH patients had higher CSF levels of sEng (0.037 vs. 0.251 ng/ml; P = 0.02) and sFlt1 (0.068 vs. 0.679 ng/ml; P = 0.001). In the subgroup analysis, sVS patients had higher CSF levels of sEng and sFlt1 than no-sVS patients (sEng: 0.380 vs. 0.159 ng/ml, P = 0.02; sFlt1: 1.277 vs. 0.343 ng/ml, P = 0.01). The serum levels of sEng and sFlt1 were not statistically different among the different groups. CONCLUSIONS: Based on these results the authors conclude that elevated CSF levels of sFlt1 and sEng herald the occurrence of symptomatic VS post SAH.
BACKGROUND: The pathogenesis of vasospasm (VS) post aneurysmal subarachnoid hemorrhage (SAH) is multifactorial and not completely understood. The authors hypothesize that circulating antiangiogenic factors play an important role in brain injury post SAH and that elevated levels predict the occurrence of symptomatic vasospasm. METHODS: In this study the authors measured the serum and cerebrospinal fluid (CSF) levels of soluble endoglin (sEng) and soluble fms-like tyrosine kinase 1 (sFlt1) in controls and SAHpatients within 48 h of the bleed. Patients were prospectively followed and subcategorized into those with (sVS) and without symptomatic vasospasm (no-sVS). RESULTS: Compared to healthy controls, SAHpatients had higher CSF levels of sEng (0.037 vs. 0.251 ng/ml; P = 0.02) and sFlt1 (0.068 vs. 0.679 ng/ml; P = 0.001). In the subgroup analysis, sVS patients had higher CSF levels of sEng and sFlt1 than no-sVS patients (sEng: 0.380 vs. 0.159 ng/ml, P = 0.02; sFlt1: 1.277 vs. 0.343 ng/ml, P = 0.01). The serum levels of sEng and sFlt1 were not statistically different among the different groups. CONCLUSIONS: Based on these results the authors conclude that elevated CSF levels of sFlt1 and sEng herald the occurrence of symptomatic VS post SAH.
Authors: Attila Molvarec; András Szarka; Szilvia Walentin; Endre Szucs; Bálint Nagy; János Rigó Journal: Hypertens Res Date: 2010-06-10 Impact factor: 3.872
Authors: Shivalingappa Venkatesha; Mourad Toporsian; Chun Lam; Jun-ichi Hanai; Tadanori Mammoto; Yeon M Kim; Yuval Bdolah; Kee-Hak Lim; Hai-Tao Yuan; Towia A Libermann; Isaac E Stillman; Drucilla Roberts; Patricia A D'Amore; Franklin H Epstein; Frank W Sellke; Roberto Romero; Vikas P Sukhatme; Michelle Letarte; S Ananth Karumanchi Journal: Nat Med Date: 2006-06-04 Impact factor: 53.440
Authors: Joshua B Bederson; E Sander Connolly; H Hunt Batjer; Ralph G Dacey; Jacques E Dion; Michael N Diringer; John E Duldner; Robert E Harbaugh; Aman B Patel; Robert H Rosenwasser Journal: Stroke Date: 2009-01-22 Impact factor: 7.914
Authors: X Ma; M Labinaz; J Goldstein; H Miller; W J Keon; M Letarte; E O'Brien Journal: Arterioscler Thromb Vasc Biol Date: 2000-12 Impact factor: 8.311
Authors: Cecil O Borel; Andy McKee; Augusto Parra; Michael M Haglund; Amy Solan; Vikas Prabhakar; Huaxin Sheng; David S Warner; Laura Niklason Journal: Stroke Date: 2003-02 Impact factor: 7.914
Authors: Caron M Hong; Cigdem Tosun; David B Kurland; Volodymyr Gerzanich; David Schreibman; J Marc Simard Journal: Biomarkers Date: 2014-02-05 Impact factor: 2.658